Summary Roquinimex (Roq) is an immunomodulator known to stimulate cellular immune responses. It is currently used for immunotherapy after bone marrow transplantation (BMT). One of the major features of this compound is an enhancement of natural killer (NK) cell activity and numbers. We studied the in vitro effect of Roq on human peripheral blood NK and adherent lymphokine-activated killer cell (ALAK) activities. In cultures supplemented with recombinant interleukin 2 (rIL-2) (1000 U ml-') and Roq a significant increase in NK and LAK function was observed without a parallel increase in cell numbers. We also examined the generation of NK cells from human bone marrow (BM) immature progenitors, obtained by purging with 4-hydroperoxycyclophosphamide (4HC). NK cell numbers and activity were both increased when cultures with rIL-2 (10 U ml-') were supplemented with Roq. These results confirm findings obtained in vivo and in vitro in the murine system and suggest that Roq is an active agent on these lymphoid populations. These properties and good tolerability make Roq an attractive tool for immunotherapy.
Roquinimex (Roq) (quinoline-3-carboxamide) is a compound that has been shown to have immunomodulator and antitumour activity in various animals and human model systems and is well tolerated. Roq was found to have therapeutic effects in primary tumours and metastasis (Kalland et al., 1985a; Kalland, 1986) , and its impact following autologous bone marrow transplantation (ABMT) for acute myelogenous leukaemia (AML) Rowe et al., 1993a) and chronic myelogenous leukaemia (CML) (Rowe et al., 1993b) is currently under investigation. Its immunomodulator properties have also proven useful in the amelioration of the autoimmune manifestations of murine encephalomyelitis (Karussis et al., 1993a,b) , collagen-induced arthritis (Kleinau et al., 1989) and lupus-like disease (Tarkowski et al., 1986a,b) as well as in parasitic and viral infections (Ilback et al., 1989) .
One of the major features of Roq is an enhancement of NK cell activity and numbers (Kalland et al., 1985b; Kalland, 1990; Bengtsson et al., 1992) . NK cells are important components of the immune system that exhibit non-MHCrestricted cytolytic activity against tumours (Herberman et al., 1979; Gorelik and Herberman, 1986; Felsher, 1990) , virus infected cells (Welsh, 1981) and tissue grafts (Lotzova et al., 1979; Cuturi et al., 1989) . Cancer patients with low NK cell activity have been found to have an increased relapse rate (Pizzolo et al., 1988) and their early recovery in the period after BMT may be essential in the eradication of residual tumour cells and defence against infection. Interleukin 2 (IL-2)-activated NK cells are LAK effectors. Adherent LAK (ALAK) cells have been shown to have more potent cytolytic activity than do unfractionated LAK cells (Melder et al., 1988; Vujanovic et al., 1988; Verfaillie et al., 1989 
Materials and methods

Reagents
Roquinimex is a quinoline-3-carboxamide, its tradename is Linomide (Pharmacia Lund, Sweden).
Production of ALAK cells Peripheral blood was obtained from healthy donors after informed consent was given. ALAK cells were produced as previously described (Melder et al., 1988; Vujanovic et al., 1988 The cells recovered at the end of culture were not derived from the total number of cells plated at day 0, but from the adherent fraction retained after decanting the non-adherent population at 24 h of culture. Therefore, the index of cell proliferation in ALAK cultures was calculated as the ratio between the number of cells in each culture and the control cultures (Figure 1 ). Cultures only supplemented with rIL-2 had the highest proliferation rate (6.0 ± 1.1) as compared with the control. By comparison, when Roq was added to rIL-2 the difference in cell expansion was not statistically significant (P = 0.3 for rIL-2 plus Roq 50 jig ml-' and P=0.1 for rIL-2 and Roq 25 1ig ml-'). Roq by itself was not able to stimulate cell proliferation (1.3 ± 1.8 at a concentration of 25 jig ml-and 0.8 ± 6.0 at 50 ig ml-'). INsis of Raji targets as compared with rIL-2 alone (in one experimiienit the increase was 32.8 at an E T ratio of 5:1 and in the other this increase was at the same E T ratio).
NK actixitv as defined by lysis of K562 targets was siliticantl\ enhanced by Roq (25 ' iml -) in cultures already supplemiiented xwith rIL-2 (P = 0.01) ( Table 11 ). The rIL-2 + Roq 50 jig ml-' cultures were not signiticantlx different trom the IL-2-actilated cells (P = 0.2). We did not observe stimulaktion of NK activity by Roq alone as compared with conitrol (P= 0.2) tor Roq 25 jig ml-' and P = 0.7 tor Roq 50 pg ml .
Bonti ;no(ii-rr-oa (tiultuires In cultures of 4HC' purged BMMNC an increase in l_tic actix itx of NK targets was obserxved in those supplemiienited x ith rl L-2 and Roq ( 14 ± 9.900 Isis at an E T ratio ot 10: 1) as compaIred with 5.7 6.1O% at the samne E T raltio for cells grown onlv with rlL-2; at other ratios, a simlar increase in Ixtic actixitv was observed (except 1.25:1 ) (Figure 3 ). Phelt-lOl'pic ont1!a.1is AIL A cultures We harvested peripheral blood from nine donors and analksed the ALAK cultures between 10 and 14 daxs of culture (Table II) Roq (25 pg ml ') (U) as compared with 11 -alone (*) 0, rl L-2 ( lOOO U nil 1) and Roq (5) pg ml--'). (Robertson and Ritz, 1990) . Roq is a quinoline derivative that has immunomodulator activity. The mode of action of Roq has been analysed mainly in animal models of autoimmune and cancer diseases where its relevance as a modulator of immunological (Kalland et al., 1985a; Kalland, 1986; Larsson et al., 1987) and non-immune mechanisms (Ichikawa et al., 1992; Vukanovic et al., 1993) has been shown. Its effect on NK function has also been shown to be important in the control of metastasis (Harning et al., 1989 (Harning et al., , 1990 .
The mechanism of action of Roq and its effects on the human systsem at the cellular level are still not well understood. Studies in human recipients of autografts suggest that Roq induces an increase in NK cell numbers and cytotoxicity against both NK-sensitive and NK-resistant targets. Roq was also capable of inducing the production of several cytokines in these patients (Bengtsson et al., 1992; Simonsson et al., 1992; Nilsson et al., 1993) .
In the clinical setting, a standard dose of 0.2 mg kg-' Roq will achieve an average blood level of 1.3 lag ml-'. We tested doses from -100 jig ml-' Roq in vitro, however it is likely that some of the effects seen in vivo are due to production of cytokines by accessory cells or to active metabolites which we could not account for in our in vitro studies. We could not demonstrate, in our system, a stimulating effect of Roq, by itself, on NK or ALAK function from peripheral blood. These observations support those described in the murine system where proliferation of NK and LAK cells was observed when Roq was administered in vivo but not in in vitro cultures of murine splenocytes (Kalland et al., 1985b) , thus suggesting that Roq acts on NK and LAK precursors. Roq added to suboptimal concentrations of rIL-2 was shown to be effective in increasing NK cell generation and cytotoxicity from murine bone marrow cultures in vitro (Kalland, 1990) . Based on these findings we decided to evaluate the effect of Roq on NK BM precursors. We have previously shown that NK cells can be derived from primitive haemopoietic progenitors (Silva and Ascensao, 1995) . 4HC purging of BMMNCs allows for maintenance of only the most primitive haemopoietic progenitors destroying populations of committed progenitors and mature cells (Moore, 1991; Rowley et al., 1993) , including active NK cells and their late precursors in BM (Cardoso et al., 1992 curve, which is a feature of quite a few immunomodulatory agents. In vitro, Roq exerts its immune cellular effects both on peripheral blood and at the bone marrow progenitor level but with different results on NK cell proliferation and cytolytic activity. These dual effects are similar to those previously reported in the murine system and suggest that different mechanisms exist for the regulation of mature and progenitor NK cells. These properties and good tolerability make Roq an attractive tool for immunotherapy.
